Healthee, an Israeli startup offering an AI-powered platform transforming healthcare cost management, has successfully raised $50 million in a Series B funding round. This latest investment signals strong market confidence in Healthee’s vision to reshape how organizations manage healthcare costs through innovative AI solutions. Also, Healthee announced a strategic partnership with the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), to provide employees with transparent, affordable access to prescription medications. By integrating Cost Plus Drugs’ direct-to-consumer pharmaceutical model into Healthee’s AI-driven benefits platform, the collaboration aims to empower employees to make informed healthcare choices while significantly reducing out-of-pocket costs. By teaming up with Mark Cuban Cost Plus Drug Company, we are taking another step toward making healthcare more transparent, affordable, and accessible.